Vol. 3 No. 8 (2023)
Reimbursement Reviews

Atogepant (Qulipta)

decorative image of the issue cover

Published August 30, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses atogepant (Qulipta), 10 mg, 30 mg, and 60 mg, oral tablets.
  • Indication: The prevention of episodic migraine (< 15 migraine days per month) in adults.